Clinical trials: Severe Eosinophilic Asthma, open to volunteers
Severe Asthma, Asthma in Children
Severe Eosinophilic Asthma Phenotypes During Childhood Have Various Origins
Study of the clinical evolution at 10 years of children from the SAMP cohort (severe asthma, eosinophilic or not, allergic or not) in order to understand the different possible evolutions of these phenotypes at different ages.
- Trial name
- SAMP 2 (NCT05762627)
- Where
- France
- Volunteers
- 360 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Asthma
Efficacy and Safety Study of 610 in Patients With Severe Asthma
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
- Trial name
- NCT06323213
- Testing
- 610
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
- Trial name
- BREADTH (NCT07323654)
- Testing
- KT-621
- Where
- 81 sites in United States, Argentina and 11 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
- Trial name
- ATHENA (NCT07214753)
- Testing
- benralizumab
- Where
- 28 sites in Italy
- Volunteers
- 335 people
- Sponsor
- AstraZeneca
Asthma; Eosinophilic, Severe Asthma
Predictive Signature of Benralizumab Response
The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic…
- Trial name
- BENRAPRED (NCT04565483)
- Testing
- Benralizumab Prefilled Syringe
- Where
- 20 sites in France
- Volunteers
- 220 people
- Sponsor
- Nantes University Hospital
EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Aim of the study is to identify potential biomarkers, through a proteomic approach, which could be used to evaluate organ damage and predict the response to mepolizumab in a cohort of patients affected by EGPA.
- Conditions
- EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma
- Trial name
- BEOMICS (NCT07343661)
- Testing
- Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Severe Eosinophilic ACOS (Asthma-COPD Overlap)
Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics
Firstly, to screen blood exosomal multi-omics (transcriptomics, proteomics, metabolomics) and lung radiomics (HRCT, Xe129MRI) biomarkers that can predict efficacy and prognosis in severe eosinophilic ACOS (asthma-COPD overlap)…
- Trial name
- ACOS (NCT07602881)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chronic Rhinosinusitis With Nasal Polyps
Real Life Study of Biologicals in Patients With Severe CRSwNP
This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment.
- Trial name
- NASUMAB (NCT05938972)
- Testing
- Mepolizumab
- Where
- Belgium
- Volunteers
- 180 people
- Sponsor
- University Hospital, Ghent
Asthma, Bronchial
A Non-interventional, Prospective Study With Benralizumab
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients…
- Trial name
- AIR POWER (NCT06422078)
- Where
- 41 sites in Germany
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma, Severe Asthma
Fasenra: An Asthma Study
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma.
- Conditions
- Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
- Trial name
- NCT07654842
- Testing
- Budesonide-albuterol, Benralizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Endeavor Health